The pricing of Biodexa's public offering is likely to have a neutral short-term impact on its stock price. While the additional capital can be beneficial for the company's growth and financial stability, the issuance of new units typically leads to dilution of existing shareholders' equity. The market's reaction will depend on investors' perception of the company's growth prospects and the use of the raised funds.